Lung metastasis following temporary discontinuation of lenvatinib and tislelizumab in hepatocellular carcinoma: A case report

BACKGROUND Hepatocellular carcinoma (HCC) is a prevalent malignancy in China, primarily diagnosed at advanced stages, which limits treatment options and increases mortality rates. Conversion therapy, which includes systemic and locoregional treatments, aims to render unresectable tumors resectable....

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastrointestinal surgery Vol. 17; no. 3; p. 100951
Main Authors Wang, Chen-Dong, Liu, Run-Dong, Liu, Ming-Jie, Song, Jia
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 27.03.2025
Subjects
Case Report
Conversion therapy
Hepatocellular carcinoma
Tislelizumab
Case report
Lenvatinib
Hepatic arterial infusion chemotherapy
Online AccessGet full text

Cover

More Information
Summary:BACKGROUND Hepatocellular carcinoma (HCC) is a prevalent malignancy in China, primarily diagnosed at advanced stages, which limits treatment options and increases mortality rates. Conversion therapy, which includes systemic and locoregional treatments, aims to render unresectable tumors resectable. Nonetheless, research is scant on the risks of disease progression during the temporary cessation of targeted drugs and immune checkpoint inhibitors before surgery. CASE SUMMARY This report describes a 58-year-old male with HCC who developed lung metastases following the discontinuation of lenvatinib and tislelizumab, revealing the necessity for further investigation into the management of HCC patients during the perioperative period, particularly concerning the timing and duration of targeted therapy and immunotherapy. CONCLUSION Our study highlights the complex challenges in managing advanced HCC and emphasizes the critical need for ongoing research to refine treatment strategies and improve patient outcomes.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
Corresponding author: Jia Song, PhD, Doctor, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan 430022, Hubei Province, China. tjhsongjia@hust.edu.cn
Author contributions: Wang CD and Liu RD performed the data analysis and wrote the manuscript; Liu MJ collected the patient's clinical findings; Song J contributed to supervising and revising the manuscript.
Co-first authors: Chen-Dong Wang and Run-Dong Liu.
ISSN:1948-9366
1948-9366
DOI:10.4240/wjgs.v17.i3.100951